These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1078314)

  • 1. Improvement of the flow properties of blood: a new therapeutical approach in occlusive arterial disease.
    Ehrly AM
    Angiology; 1976 Mar; 27(3):188-96. PubMed ID: 1078314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of pentoxifylline on the flow properties of human blood.
    Ehrly AM
    Curr Med Res Opin; 1978; 5(8):608-13. PubMed ID: 710175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of pentoxifylline on the deformability of erythrocytes and on the muscular oxygen pressure in patients with chronic arterial disease.
    Ehrly AM
    J Med; 1979; 10(5):331-8. PubMed ID: 294470
    [No Abstract]   [Full Text] [Related]  

  • 4. Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication.
    Dawson DL; Zheng Q; Worthy SA; Charles B; Bradley DV
    Angiology; 2002; 53(5):509-20. PubMed ID: 12365857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease.
    Perego MA; Sergio G; Artale F; Giunti P; Danese C
    Curr Med Res Opin; 1986; 10(2):135-8. PubMed ID: 3709212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentoxifylline -- a biomedical profile.
    Müller R
    J Med; 1979; 10(5):307-29. PubMed ID: 393789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentoxifylline treatment in patients with occlusive peripheral arterial disease. Circulatory changes and effects on prostaglandin synthesis.
    Poggesi L; Scarti L; Boddi M; Masotti G; Serneri GG
    Angiology; 1985 Sep; 36(9):628-37. PubMed ID: 3901827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and hemorrheologic effects of pentoxifylline in patients with obliterative arteriopathy of the legs].
    Vaya A; Martínez M; Carbonell P; Aznar J
    Angiologia; 1987; 39(6):262-8. PubMed ID: 3425972
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions.
    Leonhardt H; Grigoleit HG
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Sep; 299(2):197-200. PubMed ID: 909613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentoxifylline and cerebrovascular diseases.
    Marcel GA; George C
    Eur Neurol; 1983; 22 Suppl 1():89-97. PubMed ID: 6350013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease.
    Angelkort B; Maurin N; Boateng K
    Curr Med Res Opin; 1979; 6(4):255-8. PubMed ID: 527350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous ancrod therapy in peripheral arterial disease: improvement in blood viscosity and nutritional blood flow.
    Lowe GD; Morrice JJ; Forbes CD; Prentice CR; Fulton AJ; Barbenel JC
    Angiology; 1979 Sep; 30(9):594-9. PubMed ID: 484913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs.
    Strano A; Davi G; Avellone G; Novo S; Pinto A
    Angiology; 1984 Jul; 35(7):459-66. PubMed ID: 6380350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of pentoxifylline on blood viscosity and peripheral hemodynamics in patients with peripheral occlusive arteriopathies].
    Guerrini M; Pecchi S; Rossi C; Cappelli R; Pieragalli D; Acciavatti A
    Ric Clin Lab; 1981; 11 Suppl 1():265-79. PubMed ID: 7188114
    [No Abstract]   [Full Text] [Related]  

  • 15. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects.
    Reilly DT; Quinton DN; Barrie WW
    N Z Med J; 1987 Jul; 100(828):445-7. PubMed ID: 3330188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of treatment with ancrod (Arwin) in 21 patients with chronic arterial occlusive disease].
    Rosendo A; Sala Planell E; Latorre J; Marinello J; Olba L; Rutllant ML
    Rev Clin Esp; 1982 Mar; 164(5):313-6. PubMed ID: 7100546
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood fluidity and coagulation phenomena in chronic arterial occlusive disease.
    Angelkort B; Boateng K; Maurin N
    J Int Med Res; 1980; 8(3):242-6. PubMed ID: 7389992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.
    Aviado DM; Dettelbach HR
    Angiology; 1984 Jul; 35(7):407-17. PubMed ID: 6380349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combination hemodilution and defibrinogenating therapy in chronic arterial occlusive diseases].
    Ehrly AM; Saeger-Lorenz K
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():332-3. PubMed ID: 349931
    [No Abstract]   [Full Text] [Related]  

  • 20. Adenine nucleotides in erythrocytes from patients with peripheral vascular disease and the effects of oxpentifylline.
    Gleeson M; Maughan RJ
    Eur J Vasc Surg; 1987 Jun; 1(3):173-9. PubMed ID: 3503768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.